Direct compression of Gandan Granules veterinary-grade API into companion animal tablets requires that the as-received granular material pass through a 1.0 mm conical screen before addition to a 600 L bin blender. Blending is performed at 8–12 rpm for 20–30 min. Flowability is measured according to USP <1174>; the accepted Carr index for this operation is 15–25%, and the Hausner ratio should not exceed 1.35. A formulation with 30% w/w Gandan Granules API, 45% w/w microcrystalline cellulose, 20% w/w lactose monohydrate, 3% w/w crospovidone, 0.8% w/w magnesium stearate, and 0.2% w/w colloidal silicon dioxide is lubricated for the final 3–5 min only. The tablet press, a 19-station rotary machine with B-tooling, operates at 60–80 rpm and 8–12 kN compression force. Weight variation is monitored per USP <905> with acceptance of ±5.0% for 650 mg target tablets and content uniformity acceptance value L1 ≤15.0. Friability is kept below 1.0% per USP <1216>. Disintegration in 900 mL water at 37±2°C conforms to USP <701> within 15 min. If the granule fraction below 150 µm exceeds 25%, segregation in the feed frame becomes measurable as content uniformity outside 90.0–110.0% label claim. Packaging is validated under 25°C/60% RH in aluminum-aluminum blisters to limit moisture ingress. Pre-drying is required if ambient RH exceeds 60%; fluid-bed drying at 50–60°C to 1.5–2.0% loss on drying by USP <731> is recommended before blending.

How Does Endotoxin Load Affect Sterile Filling of Aqueous Veterinary Injections?

Aseptic preparation of Gandan Granules veterinary-grade API for parenteral use begins with dissolution in Water for Injection at 20–40°C with 300–500 rpm overhead agitation. The granular state is not sterile and must be depyrogenated, sterile-filtered, and filled under EU GMP Annex 1 conditions. If the API has oxygen-sensitive moieties, nitrogen overlay at 0.2–0.5 bar positive pressure is applied. The bulk solution is passed first through 0.45 µm polyethersulfone and then through 0.22 µm PVDF sterilizing-grade filters in a Grade C background with Grade A local protection per ISO 14644-1 Class 5. Endotoxin reduction is verified by Ph. Eur. 2.6.14 kinetic chromogenic LAL; the acceptance limit is stated in the finished product monograph, and for multi-dose parenterals the use of 1.5% v/v benzyl alcohol requires compatibility testing according to Ph. Eur. 5.6. If the dissolved formulation is sufficiently heat-stable, terminal steam sterilization at 121°C for 15 min is preferred over aseptic filtration because it provides a sterility assurance level of ≤10⁻⁶. If thermal degradation occurs above 80°C, aseptic filtration remains the only option and the batch must be filled within 4 h of sterile filtration to control bioburden. Vial filling on a 100–400 vials/min linear peristaltic line uses in-process weight check every 5 min and 100% visual inspection per USP <790>. Sub-visible particulate burden is controlled to ≥10 µm: ≤6000 and ≥25 µm: ≤600 per container as described in USP <788>. Container closure integrity is verified by vacuum decay per USP <1207>. Do not compound with divalent cation-containing diluents if precipitation of phosphate or sulfate salts is observed during small-volume compatibility screening; published data for this specific configuration is limited and a pre-formulation robustness study under 2–8°C and 25°C/60% RH is required before scale-up.

Premix Uniformity and Carryover Control in 1:1000 Dilution Systems

Production-scale feed mills receive Gandan Granules API as a granular concentrate for intermediate premix manufacturing. Carrier particle size is matched to the API granule within 150–500 µm to reduce percolation segregation. A 500 kg double-shaft paddle mixer operating at 25 rpm for 8 min produces a coefficient of variation below 5.0% when sampled at 10 thief points. The intermediate premix is prepared by mixing 1 part API granules with 999 parts ground rice hull or calcium carbonate in a 200 kg V-blender for 12 min. Final feed incorporation uses 5–10 kg of intermediate premix per 1000 kg finished feed in a 2 t horizontal paddle mixer for 6–8 min. Carryover into subsequent batches must be quantified by assay of the first 10 kg flushed material; the acceptance criterion is ≤1.0% of the previous batch active content. Cleaning validation follows 21 CFR 211.67 and should include swab recovery from ribbon screw, dead-space corners, and discharge gate. Blend uniformity can be supported by near-infrared spectroscopy at 10 sampling positions with recovery limits of 90.0–110.0%. The following dilution matrix is used during scale-up.

In hard water with 300–500 mg/L CaCO₃ equivalents, dissolution of Gandan Granules API for drinking-water medication systems is limited by total hardness and pH above 7.5. A stock solution is prepared at 1.0% w/v in 25–35°C water using 300 rpm propeller agitation for 10 min; if visual settling exceeds 2 min, add 0.2–0.5% w/w citric acid or 0.1% w/w EDTA disodium to chelate hardness ions. The resulting stock solution is dosed through an inline medicator at 1:100 to produce a final drinking-water concentration in the range 0.5–1.0 g/L, subject to veterinary prescription and species-specific water intake. Solubility is verified by USP <1236> equilibrium solubility testing at 25±0.5°C; a clear-to-slightly-opalescent solution without visible precipitation after 6 h is the minimum acceptance criterion. If the granule formulation is not self-wetting, 0.5% w/w poloxamer 188 may be added, but compatibility with hard water and residual chlorine at 0.2–0.5 ppm must be screened. Sachets of soluble powder are packed in aluminum-lined pouches under ≤25°C and ≤60% RH; moisture content is confirmed below 2.0% by Karl Fischer titration. Batch-to-batch variation in granule bulk density between 0.45–0.60 g/mL affects sachet fill weight uniformity and requires auger filler adjustment; relative standard deviation of fill weight should remain ≤2.0%.

When Granule Friability Approaches 3% During Rotary Tablet Compression

If the as-supplied Gandan Granules API generates fines above 3% friability during tablet compression, the operation shifts from direct compression to roller compaction or wet granulation. On a 19-station rotary press at 60–80 rpm, pre-compression force is set at 4–6 kN and main compression at 8–12 kN; capping becomes visible when tablet hardness falls below 60 N. In wet granulation, 5% w/w povidone K30 solution is sprayed into a high-shear mixer at 300 rpm impeller and 1500 rpm chopper for 3–5 min, then the wet mass is dried in a fluid-bed dryer at 50–60°C until loss on drying is 1.5–2.5% by USP <731>. The dried granules are sized through a 1.0 mm screen and lubricated with 0.5% w/w magnesium stearate for 3 min. Tablet weight is 650 mg ±5%, hardness 70–100 N, disintegration ≤15 min in 900 mL water at 37±2°C by USP <701>. If ambient RH exceeds 60%, the granules absorb moisture; pre-drying in a tray dryer at 45–50°C for 60–90 min is required before compression. Avoid combining the wet granulation with amine-based excipients if the active moiety contains aldehyde or ketone groups, as Schiff-base formation may reduce assay. Published data for this specific configuration is limited; a forced degradation study under 40°C/75% RH and UV/Vis 320–400 nm is recommended before locking the formulation.

Capsule Fill Weight Drift Across Tamping Pin Cycles in Size 3 Hard Gelatin Capsules

Automatic dosator/tamping-pin encapsulation of Gandan Granules API at 15,000 capsules/h produces fill weight drift when the blend is over-lubricated or contains excessive fines. A size 3 hard gelatin capsule with 250 mg ±5% target fill uses 20% w/w API granules, 45% w/w lactose monohydrate, 20% w/w microcrystalline cellulose, 3% w/w croscarmellose sodium, 0.5% w/w magnesium stearate, and 0.2% w/w colloidal silicon dioxide. Tamping pin penetration is set at 5 mm, 10 mm, and 15 mm for three successive stations; fill weight drift beyond 6.0% indicates overlubrication, requiring magnesium stearate reduction to 0.25% w/w. In-process weight checks are performed every 15 min with acceptance of 90.0–110.0% label claim. Powder flow is measured by USP <1174>; a Carr index above 25% will cause inconsistent plug formation. Moisture content below 3.0% prevents gelatin crosslinking during storage at 25°C/60% RH. Dissolution is tested by USP <711> Apparatus 2 at 50 rpm in 900 mL 0.1 M HCl at 37.0±0.5°C; the Q-value is 80% released at 45 min. Capsule shells are selected from BSE-free bovine or porcine gelatin with 13.0–15.0% moisture as per supplier certificate; if hydroxypropyl methylcellulose shells are used, equilibrium moisture at 25°C/60% RH is 4.0–6.0%.

Post-pellet top-dressing of Gandan Granules API onto pelleted feed avoids the 80–85°C conditioning temperature used in steam pelleting, which can degrade thermally labile actives during 30–60 s residence time. A dry electrostatic applicator or post-pellet liquid spray system applies 0.5–2.0 kg granules per 1000 kg cooled pellets. To achieve surface adhesion, the pellets are first coated with 0.5–1.0% w/w soybean oil in a rotary drum; the API granules with particle size 300–800 µm are then added and mixed for 2–3 min. Uniformity is verified by collecting 10 samples across the discharge flow; coefficient of variation should remain ≤8.0% because top-dress distribution is less homogeneous than a full premix. If pellet temperature exceeds 40°C during application, oil viscosity falls and granule adhesion drops; cooling to 25–35°C is required. This route is used for solid oral dosage in ruminants and swine where water medication is impractical; protected packaging in 25 kg paper sacks with PE liner is acceptable only when storage is ≤25°C and ≤60% RH. Batch-to-batch granule friability above 3% increases dust losses during pneumatic conveying and lowers assay recovery in field samples. Cleaning of the top-dress mixing drum after each batch follows 21 CFR 211.67, with swab limits for active residue not exceeding 10 ppm.